Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition.

Slides:



Advertisements
Similar presentations
Pharmacy Benefit Managers (PBMs)
Advertisements

Labor’s Fight to Get Medicare for All Reg Clark & Matthew Kogan Labor United for Universal Health Care Healthy California Campaign 3 rd Annual Summer Conference.
 Medicare Drug Rebates  Medicare patients who face a gap in prescription drug coverage would received a one-year, $250 rebate to help pay for medication.
Controlling Drug Prices: What Canada Does Joel Lexchin MD School of Health Policy & Management York University.
Reviewing the Canadian Drug Landscape and Generic Pricing Models CGPA CONFERENCE - 26 OCTOBER 2011 François Joseph Poirier Partner Toronto Bay Street.
Health Care for All Colorado Irene Aguilar, M.D. Vice President, Health Care for All Colorado Primary Care Physician Westside Health Center Denver Health.
Healthcare Reforms That Might Work Sam Clovis, Jr. Doctor of Public Administration Morningside College.
Implementing ICP Recommendations Financing The Road To Prosperity Paul Daniel Muller President Montreal Economic Institute.
An Application of the Quebec’ s General Equilibrium Model Impact of the Elimination of the 15-year Rule Ministère des Finances, Politiques économiques.
MEDICARE: PAST, PRESENT AND FUTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.
317_L15, Feb 8, 2008, J. Schaafsma 1 Review of the Last Lecture began our discussion of why there is a demand for health insurance basic reason => people.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Critical Condition: How Health Care in America Became Big Business & Bad Medicine Donald L. Barlett & James B. Steele.
PUBLIC & PRIVATE HEALTH CARE IN CANADA before the Canadian Pension & Benefits Institute Winnipeg - June 15, 2007 by Norma Kozhaya, Ph.D. Economist, Montreal.
Major Health Issues The Affordable Healthcare Act.
The Private Health Insurance Market. Insurance Design Insurance is designed to spread risk Individuals can self-insure and face chance of paying for costs.
The Facts About Rising Health Care Costs.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Health care system in Belgium How Belgian patients can save 1 billion euro / year and the health insurance system 1,6 billion / year …
Proposals for “Universal” Health Care or Back to the Health Care Future Leonard Rodberg Urban Studies Dept., Queens College/CUNY and NY Metro Chapter Physicians.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Health Care Reform Quynh Smith. Sources of Inefficiency in the Health Care Delivery System   We spend a substantial amount on high cost, low-value treatments.
What Wonders Have They Wrought? The Patient Protection and Affordable Care Act.
Health Reform: What It Means to Our Community. Health Reform: Key Provisions o Provides coverage to 32 million uninsured people by o Changes insurance.
2005 Budget Summit February 11, 2005 Paula A. Bussard SVP, Policy & Regulatory Services The Hospital & Healthsystem Association of Pennsylvania.
Ideas Changing the World Health Reform Mean for You? Does What.
“Improved Medicare For All” for Beginners (Part A)
CH 1. Factors accounting for the growth of importance in the health sector  Global health and longevity gains  Expansion of health sector throughout.
Lukas Steinmann Mexico 10. June 2008 To your health: diagnosing the state of healthcare and the global private medical insurance industry.
To Accompany “Economics: Private and Public Choice 13th ed.” James Gwartney, Richard Stroup, Russell Sobel, & David Macpherson Slides authored and animated.
To Accompany “Economics: Private and Public Choice 10th ed.” James Gwartney, Richard Stroup, Russell Sobel, & David Macpherson Slides authored and animated.
Exhibit 1. “Medicare Extra” Benefits vs. Current Medicare Benefits Current Medicare benefits*“Medicare Extra” Deductible Hospital: $1024/benefit period.
Chapter 22 Health Care Copyright © 2010 by The McGraw-Hill Companies, Inc. All rights reserved.McGraw-Hill/Irwin.
A System in Need of Fundamental Reform Dennis Lazof, Ph.D. Treasurer, Founding Member Health Care for All NC Director, Project.
Political Economy.
Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.
Medicare, Medicaid, and Health Care Reform Todd Gilmer, PhD Professor of Health Policy and Economics Department of Family and Preventive Medicine 1.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
McGraw-Hill/Irwin Copyright © 2012 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 23 Health Care.
McGraw-Hill/Irwin © 2002 The McGraw-Hill Companies, Inc., All Rights Reserved. Chapter 20 Health Care.
Domestic Policy Social Welfare and Health. 3 The Evolution of Social Welfare Policies  Most of our major federal social welfare programs were developed.
Managed Care & Health Care Reform Cost of Health Care $2.4 trillion in 2008 ($7.900 per person) 17% of GDP US 10.9% Switzerland 10.7% Germany 9.7% Canada.
Chapter 9. Section 1 Civics: Government and Economics in Action3  Government ◦ The government plays an important role in the American economy, by making.
Reforming Health Care: Making Sense of Health Care Finance amid Growing Underinsurance Leonard Rodberg, PhD Urban Studies Dept., Queens College/CUNY Prepared.
Controlling Drug Prices: What Canada Does
Wisconsin’s Challenges in Health Care Access and Cost: A Look at the Numbers March 22, 2006 Donna Friedsam, MPH Associate Director for Health Policy University.
Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.
Health Care Chapter 21 McGraw-Hill/Irwin Copyright © 2009 by The McGraw-Hill Companies, Inc. All rights reserved.
Social Programs and Taxation. What is a Social Program?? - services provided by the government to reduce economic inequalities and promote the well-being.
Universal Health Care without Private Health Insurance? Single Payer: The Only Affordable, Lifelong, Comprehensive, Quality Health Care Plan for Every.
1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Alcoholtaxessavelives.org Julie Martinez, Chris Weathers, Cassandra Romero.
Chapter 22 Health Care Copyright © 2015 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of.
22 CHAPTER PUBLIC SECTOR ECONOMICS: The Role of Government in the American Economy Randall Holcombe Health Care.
U.S. Health Care System – Jenny Lee INEKO, Michigan Law School Student June 14, 2004.
THE NEW YORK HEALTH ACT: Single Payer Health Care for New York State May 2016.
Government and the Economy. Role of Government: Providing Public Goods Private Goods: must be purchased to be consumed; can’t be consumed by anyone else.
The Big Healthcare Issues
24 Health Care McGraw-Hill/Irwin
The Physicians Proposal for a National Pharmaceutical Program
Government’s Role in the economy
The Impact of Health Reform
The U.S. Health Care System: An International Perspective
Whole Washington Better healthcare for less
Prescription for Pharmaceutical Reform: Healing an Ailing System
The Impact of Health Reform
Prescription drug prices: Recent trends and opportunities for change
Medicare Rx Drug Benefit
Presentation transcript:

Universal Pharmacare: Solving Canada’s Drug Problem Pharmacare Forum Windsor Public Library, April 26, 2011 Canadian Health Coalition

Canada’s Drug Problem 1. No ability to control costs, rising 10.5% a year 2.Drug are overpriced – Canada 3 rd highest in world 3.8 million Canadians uninsured or underinsured 4.Prescription drug over-use and misuse especially with children and the elderly 5.New drugs rushed to market based on secret, dubious data. Rx drugs are 4 th leading cause of death

Pharma’s 7 Deadly Sins 1. Conducts unethical clinical trials 2.Ghost-writes studies, hides negative results and promotes illegal off-label use to doctors 3.Bribes doctors, pharmacists and medical researchers 4.Advertises hazardous drugs with misleading information 5.Invents illnesses in order to sell more drugs 6.Buys silence from regulators and politicians 7.Prevents the poor from getting medicines

Illegal off-label promotion to MD’s

Big Pharma Profits compared to Fortune 500 firms ( ; in millions of constant 1984 US$) Source: Fortune

Dominant Business Model: massive promotion of ‘me-too’ drugs & control over Medical Knowledge Sales: $239.8 billion R&D: $24.1 billion (10% of revenues) Promotion: $57.5 billion (24.4% of revenues) Promotion directed towards physicians: $42.8 billion Average promotion spending per physician: $61,000 1 drug rep for every 6 physicians Undisclosed promotion: Fellowships, ghostwriting, « off-label », seeding trials, astro-turf groups… Merck made $12.9 billion in 2009 and then closed its research lab in Montreal (180 jobs lost)

Retail price for an identical volume of pharmaceutical products OECD countries, 2005 (US$, market exchange rate) Source: OECD Eurostat OECD PPP Programme, 2007.

Most New Drugs Have No Significant Advantage CategoryPercent Nothing new51% Possibly helpful21% Harmful14% Offers an advantage7% Judgement reserved5% A real advance2% Major breakthrough0.2% Total100.0 Source: France , Préscrire International, 2011

Direct-to-consumer-advertising Drives up prescription drugs costs Fails to inform Compromises public safety: exposure to dangerous drugs before risks are fully recognized, Additionally, most new drugs are costlier than existing treatments, but few provide any therapeutic advantage. Promotes the medicalisation of normal life

The Economic Case for Universal Pharmacare

Pharmacare Savings - A Current expenditure on prescription drugs $ B Growth in expenditures from increased use +10% Reduction from decrease in dispensing fees - 2% Reduction from drug assessment - 8% Elimination of the monthly deductible in Qc $144M Elimination of rebate system for generics$1.3B Elimination of the 15-year rule in Quebec $102M Change PMPRB price fixing$1.43B Elimination of extra costs for private plans $560M Elimination of tax subsidies$933M Total net savings annually $ 4.479B

Pharmacare Savings - B Savings from competitive purchasing $10.2 B Growth in expenditures from increase in use +10% Reduction from decrease in dispensing fees -2% Elimination of the deductible in Qc$ 144M Elimination of the 15-year rule in Quebec$102M Elimination of extra costs of private plans$ 560M Elimination of tax subsidies$ 933M Total savings annually $ Billion

Industrial Policies = Total Failure Innovation policies are justified by the multiplying effect on the benefits it creates as compared to costs. With a negative multiplying effect, innovation policies in the pharmaceutical sector are a total failure: Canada spends $7.4 billion in subsidies Value-added in return is only $4.8 billion

Rx spending up 73.7% CANADA, , per capita, inflation adjusted

Public spending is stable

Replace our patchwork U.S.-style drug insurance plans with universal, first-dollar coverage (no deductible or co-pay) Pay only for drugs that have been independently established to be safe and cost-effective Establish a National formulary End the price-fixing and public subsidies of Big Pharm Start bulk purchasing Universal Pharmacare will save $ billions

Pay for What Works

Next steps for Canadians “Democracy is the thing that lets ordinary people do extraordinary things. There isn’t anything we can’t accomplish if we set our minds to it.” - Tommy Douglas